Trial Profile
A Study to Investigate the Effect of Increased Gastric pH From the Administration of the Proton Pump Inhibitor (PPI) Rabeprazole on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Jan 2016
Price :
$35
*
At a glance
- Drugs Seltorexant (Primary) ; Rabeprazole
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 08 Jan 2016 Status changed from not yet recruiting to completed as per ClinicalTrials.gov record.
- 22 Jun 2015 New trial record